(Q39177322)

9 September 2017

title

Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β-catenin-dependent pathway (English)

1 reference

9 September 2017

main subject

squamous cell carcinoma

1 reference

tongue squamous cell carcinoma

inferred from title

1 reference

Li-Ping Wang

1 reference

9 September 2017

Shu-Wei Chen

1 reference

9 September 2017

Shi-Min Zhuang

1 reference

9 September 2017

Huan Li

1 reference

9 September 2017

Ming Song

1 reference

9 September 2017

publication date

22 March 2013

1 reference

Pathology and Oncology Research

9 September 2017

published in

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

461-474

1 reference

Oral cavity cancers at a young age: analysis of patient, tumor and treatment characteristics in Chiang Mai University Hospital.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectinomics: finding themes in complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

God must love galectins; he made so many of them

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectins: structure, function and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Diagnostic utility of galectin-3 in thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Regulation of prostate cancer progression by galectin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Wnt/beta-catenin signalling pathway following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

A possible role for the WNT-1 pathway in oral carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

The promise and perils of Wnt signaling through beta-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

A positive role of cadherin in Wnt/β-catenin signalling during epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Secreted antagonists of the Wnt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectins as modulators of tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3, a novel binding partner of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

The Wnt signaling pathway in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Mapping of the Wnt/β-catenin/TCF response elements in the human versican promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

JNK signalling modulates intestinal homeostasis and tumourigenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

The links between transcription, beta-catenin/JNK signaling, and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

National Cancer Database report on cancer of the head and neck: 10-Year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9603-7

Galectin-3 as a multifunctional protein

21 January 2018

1 reference

12 December 2020

Caught up in a Wnt storm: Wnt signaling in cancer

1 reference

12 December 2020

Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma

1 reference

12 December 2020

Prognostic significance of the distribution of neck node metastasis from oral carcinoma

1 reference

12 December 2020

Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity

1 reference

12 December 2020

Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer

1 reference

12 December 2020

Smad1, beta-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription.

1 reference

12 December 2020

Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties

1 reference

12 December 2020

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy

1 reference

12 December 2020

10.1007/S12253-013-9603-7

Identifiers

DOI

1 reference

9 September 2017

1 reference